Serotonin and molecular neuroimaging in humans using PET
暂无分享,去创建一个
[1] W. Danysz,et al. Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity , 2011, Behavioural pharmacology.
[2] P. Blier,et al. Pharmacological Blockade of 5-HT7 Receptors as a Putative Fast Acting Antidepressant Strategy , 2011, Neuropsychopharmacology.
[3] Gitte M Knudsen,et al. Measuring Endogenous 5-HT Release by Emission Tomography: Promises and Pitfalls , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[4] I. Page,et al. Serotonin content of some mammalian tissues and urine and a method for its determination. , 1953, The American journal of physiology.
[5] Claus Svarer,et al. Cortical and Subcortical 5-HT2A Receptor Binding in Neuroleptic-Naive First-Episode Schizophrenic Patients , 2008, Neuropsychopharmacology.
[6] Rupert Lanzenberger,et al. Central serotonin 1A receptor binding in temporal lobe epilepsy: A [carbonyl-11 C]WAY-100635 PET study , 2010, Epilepsy & Behavior.
[7] Wolfgang Wadsak,et al. Reduced Serotonin-1A Receptor Binding in Social Anxiety Disorder , 2007, Biological Psychiatry.
[8] K. Wimalasena. Vesicular monoamine transporters: Structure‐function, pharmacology, and medicinal chemistry , 2011, Medicinal research reviews.
[9] Alan A. Wilson,et al. Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB , 2000, European Journal of Nuclear Medicine.
[10] Alan A. Wilson,et al. Relationship of monoamine oxidase A binding to adaptive and maladaptive personality traits , 2010, Psychological Medicine.
[11] M. Nishikawa,et al. Increasing blood oxygen increases an index of 5-HT synthesis in human brain as measured using α-[11C]methyl-l-tryptophan and positron emission tomography , 2005, Neurochemistry International.
[12] R. Parsey,et al. Synthesis and in vivo evaluation of [O-methyl-11C] N-[3,5-dichloro-2-(methoxy)phenyl]-4-(methoxy)-3-(1-piperazinyl)benzenesulfonamide as an imaging probe for 5-HT6 receptors. , 2011, Bioorganic & medicinal chemistry.
[13] R. Eglen,et al. The pharmacology and distribution of human 5‐hydroxytryptamine2B (5‐HT2b) receptor gene products: comparison with 5‐HT2a and 5‐HT2c receptors , 1995, British journal of pharmacology.
[14] T. Machu. Therapeutics of 5-HT3 receptor antagonists: current uses and future directions. , 2011, Pharmacology & therapeutics.
[15] Feng,et al. Synthesis of a New , 2001 .
[16] M. Didriksen,et al. Effects of the 5-HT6 receptor antagonist, SB-271046, in animal models for schizophrenia , 2002, Pharmacology Biochemistry and Behavior.
[17] R. Wise,et al. Elevated Expression of 5-HT1B Receptors in Nucleus Accumbens Efferents Sensitizes Animals to Cocaine , 2002, The Journal of Neuroscience.
[18] O. Curet,et al. Mapping the Cerebral Monoamine Oxidase Type A: Positron Emission Tomography Characterization of the Reversible Selective Inhibitor [11C]Befloxatone , 2003, Journal of Pharmacology and Experimental Therapeutics.
[19] C. Marsden,et al. Influence of social isolation in the rat on serotonergic function and memory – Relevance to models of schizophrenia and the role of 5-HT6 receptors , 2011, Neuropharmacology.
[20] Junchao Tong,et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. , 2007, Brain : a journal of neurology.
[21] W. van den Brink,et al. Serotonin and dopamine transporters in relation to neuropsychological functioning, personality traits and mood in young adult healthy subjects , 2010, Psychological Medicine.
[22] A. van Waarde,et al. Measuring serotonin synthesis: from conventional methods to PET tracers and their (pre)clinical implications , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[23] R. Kvetňanský,et al. Vesicular Monoamine Transporters (VMATs) in Adrenal Chromaffin Cells: Stress-Triggered Induction of VMAT2 and Expression in Epinephrine Synthesizing Cells , 2010, Cellular and Molecular Neurobiology.
[24] David Julius,et al. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors , 1995, Nature.
[25] Laurent Descarries,et al. Decreased [18F]MPPF Binding Potential in the Dorsal Raphe Nucleus After a Single Oral Dose of Fluoxetine: A Positron-Emission Tomography Study in Healthy Volunteers , 2008, Biological Psychiatry.
[26] G. Mcallister,et al. The hypothermic effect of 5-CT in mice is mediated through the 5-HT7 receptor , 2003, Neuropharmacology.
[27] A. Meneses. Effects of the 5-HT6 receptor antagonist Ro 04-6790 on learning consolidation , 2001, Behavioural Brain Research.
[28] Kirk W. Johnson,et al. 5‐HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs , 1997, Neuroreport.
[29] Rupert Lanzenberger,et al. Aggression is related to frontal serotonin‐1A receptor distribution as revealed by PET in healthy subjects , 2009, Human brain mapping.
[30] R. Hen,et al. Attenuated Response to Stress and Novelty and Hypersensitivity to Seizures in 5-HT4 Receptor Knock-Out Mice , 2004, The Journal of Neuroscience.
[31] C. Rowe,et al. In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease. , 2011, Archives of neurology.
[32] H. Kung,et al. Amino- and amido-tetrabenazine derivatives: synthesis and evaluation as potential ligands for the vesicular monoamine transporter. , 1995, Nuclear medicine and biology.
[33] M. Erlander,et al. A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms , 1993, Neuron.
[34] U. Reuter,et al. 5-HT1F receptor agonists: A new treatment option for migraine attacks? , 2010, Neurotherapeutics.
[35] Yiyun Huang,et al. Development of effective PET and SPECT imaging agents for the serotonin transporter: has a twenty-year journey reached its destination? , 2010, Current topics in medicinal chemistry.
[36] C. Halldin,et al. Dose-dependent binding of AZD3783 to brain 5-HT1B receptors in non-human primates and human subjects: a positron emission tomography study with [11C]AZ10419369 , 2011, Psychopharmacology.
[37] S. Gambhir,et al. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. , 2003, Genes & development.
[38] Mark Slifstein,et al. Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [11C]McN 5652 , 2003, Biological Psychiatry.
[39] A. Wesołowska,et al. Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression , 2006, Neuropharmacology.
[40] S. Mace,et al. Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression , 2000, Expert opinion on pharmacotherapy.
[41] N. Volkow,et al. Monoamine oxidase: radiotracer development and human studies. , 2000, Methods.
[42] Franz X Vollenweider,et al. Serotonin research: contributions to understanding psychoses. , 2008, Trends in pharmacological sciences.
[43] David R. Thomas,et al. 5-ht5A receptors as a therapeutic target. , 2006, Pharmacology & therapeutics.
[44] Yiyun Huang,et al. Serotonin 1B Receptor Imaging in Alcohol Dependence , 2009, Biological Psychiatry.
[45] A. Varghese,et al. The serotonin transporter: a vehicle to elucidate pulmonary hypertension? , 2004, Circulation research.
[46] G. Kirov,et al. Case-control association study of 65 candidate genes revealed a possible association of a SNP of HTR5A to be a factor susceptible to bipolar disease in Bulgarian population. , 2009, Journal of affective disorders.
[47] Á. Pazos,et al. Autoradiographic distribution of 5‐HT7 receptors in the human brain using [3H]mesulergine: comparison to other mammalian species , 2004, British journal of pharmacology.
[48] W. Mcbride,et al. Serotonin-3 receptors in the posterior ventral tegmental area regulate ethanol self-administration of alcohol-preferring (P) rats. , 2010, Alcohol.
[49] C. Halldin,et al. Quantitative analysis of ( 11 C)AZ10419369 binding to 5-HT 1B receptors in human brain , 2011 .
[50] A. Serretti,et al. The 5-HT2C receptor as a target for mood disorders , 2004, Expert opinion on therapeutic targets.
[51] G. Hutchins,et al. Synthesis of new carbon-11 labeled benzoxazole derivatives for PET imaging of 5-HT(3) receptor. , 2008, European journal of medicinal chemistry.
[52] A. Meneses,et al. Stimulation of 5-HT1A, 5-HT1B, 5-HT2A/2C, 5-HT3 and 5-HT4 receptors or 5-HT uptake inhibition: Short- and long-term memory , 2007, Behavioural Brain Research.
[53] G. Debonnel,et al. Selective Serotonin Reuptake Inhibitors Potentiate the Rapid Antidepressant-Like Effects of Serotonin4 Receptor Agonists in the Rat , 2010, PloS one.
[54] P. Marin,et al. GPCR interacting proteins (GIPs) in the nervous system: Roles in physiology and pathologies. , 2010, Annual review of pharmacology and toxicology.
[55] M. Millan,et al. Differential influence of selective 5-HT5A vs 5-HT1A, 5-HT1B, or 5-HT2C receptor blockade upon light-induced phase shifts in circadian activity rhythms: Interaction studies with citalopram , 2009, European Neuropsychopharmacology.
[56] O Muzik,et al. Human brain serotonin synthesis capacity measured in vivo with alpha-[C-11]methyl-L-tryptophan. , 1998, Synapse.
[57] Paul J. Harrison,et al. 5-HT1A and 5-HT2A Receptor mRNAs and Binding Site Densities Are Differentially Altered in Schizophrenia , 1996, Neuropsychopharmacology.
[58] L. Daws,et al. Ontogeny and regulation of the serotonin transporter: providing insights into human disorders. , 2011, Pharmacology & therapeutics.
[59] Claus Svarer,et al. Cerebral serotonin transporter binding is inversely related to body mass index , 2010, NeuroImage.
[60] Rupert Lanzenberger,et al. Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram , 2009, International clinical psychopharmacology.
[61] P. Cowen,et al. Brain serotonin transporter binding in former users of MDMA ('ecstasy'). , 2009, The British journal of psychiatry : the journal of mental science.
[62] M. Leopoldo,et al. The serotonin 5-HT7 receptor agonist LP-44 microinjected into the dorsal raphe nucleus suppresses REM sleep in the rat , 2008, Behavioural Brain Research.
[63] R. Koeppe,et al. In vivo imaging of the brain vesicular monoamine transporter. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[64] J. Halford. The Role of Serotonin in Eating Behavior: Focus on 5-HT2C Receptors , 2011 .
[65] Á. Pazos,et al. Differential Distribution of [3H]Sumatriptan Binding Sites (5-HT1B, 5-HT1D and 5-HT1F Receptors) in Human Brain: Focus on Brainstem and Spinal Cord , 1997, Neuropharmacology.
[66] Z. Bhagwagar,et al. The 5-HT1B receptor: a novel target for the pathophysiology of depression. , 2009, Current drug targets.
[67] Joel Paris,et al. Brain Regional α-[11C]Methyl-l-Tryptophan Trapping in Impulsive Subjects With Borderline Personality Disorder , 2001 .
[68] I. Martin,et al. Molecular biology of 5-HT receptors , 1994, Neuropharmacology.
[69] F. Lezoualc’h,et al. Design, synthesis, and biological evaluation of new 5-HT4 receptor agonists: application as amyloid cascade modulators and potential therapeutic utility in Alzheimer's disease. , 2009, Journal of medicinal chemistry.
[70] R Todd Ogden,et al. In vivo Serotonin-Sensitive Binding of [11C]CUMI-101: A Serotonin 1A Receptor Agonist Positron Emission Tomography Radiotracer , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[71] Juha Markkula,et al. Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C]WAY-100635. , 2008, The international journal of neuropsychopharmacology.
[72] N. Costes,et al. Brainstem changes in 5-HT1A receptor availability during migraine attack , 2011, Cephalalgia : an international journal of headache.
[73] B. Herpertz-Dahlmann,et al. 5-HT2A promoter polymorphism −1438G/A in children and adolescents with obsessive-compulsive disorders , 2002, Molecular Psychiatry.
[74] M Diksic,et al. Differences between males and females in rates of serotonin synthesis in human brain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[75] D. Weinberger,et al. Central serotonin transporter levels are associated with stress hormone response and anxiety , 2011, Psychopharmacology.
[76] J. Palacios,et al. Serotonin receptors in the human brain—IV. Autoradiographic mapping of serotonin-2 receptors , 1987, Neuroscience.
[77] John F. G. Atack,et al. Serotonin Transporter , 2021, Encyclopedia of Evolutionary Psychological Science.
[78] B. Mcwilliams,et al. Cognitive Function , 2021, Encyclopedia of Gerontology and Population Aging.
[79] D. E. Kuhl,et al. Kinetic Evaluation of [11C]Dihydrotetrabenazine by Dynamic PET: Measurement of Vesicular Monoamine Transporter , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[80] M. Ramírez,et al. 5-HT(6) receptor and cognition. , 2011, Current opinion in pharmacology.
[81] D. Collier,et al. 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. , 1998, Human molecular genetics.
[82] S Kasper,et al. Influence of escitalopram treatment on 5-HT1A receptor binding in limbic regions in patients with anxiety disorders , 2009, Molecular Psychiatry.
[83] Gwenn S. Smith,et al. Functional neuroimaging in geriatric depression. , 2011, The Psychiatric clinics of North America.
[84] Markus Piel,et al. 18F-labeling and evaluation of novel MDL 100907 derivatives as potential 5-HT2A antagonists for molecular imaging. , 2010, Nuclear medicine and biology.
[85] L. Marner,et al. Cerebral serotonin 4 receptors and amyloid-β in early Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.
[86] A. Roberts,et al. The 5‐HT7 receptor in learning and memory , 2012, Hippocampus.
[87] B. Gulyás,et al. Development of a PET radioligand for the central 5-HT1B receptor: radiosynthesis and characterization in cynomolgus monkeys of eight radiolabeled compounds. , 2011, Nuclear medicine and biology.
[88] R. Regenthal,et al. The serotonin transporter availability in untreated early-onset and late-onset patients with obsessive-compulsive disorder. , 2011, The international journal of neuropsychopharmacology.
[89] Sylvain Houle,et al. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. , 2006, Archives of general psychiatry.
[90] C. D. Arnett,et al. Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. , 1987, Science.
[91] P. Cumming,et al. Effects of monoamine inhibition on amphetamine-evoked changes in dopamine receptor availability in living pig: A dual tracer PET study with 11C-harmine and 11C-raclopride , 2006 .
[92] D. Nutt,et al. Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study. , 2008, The British journal of psychiatry : the journal of mental science.
[93] H. Kung,et al. In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease. , 2010, Nuclear medicine and biology.
[94] Claus Svarer,et al. Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. , 2005, The international journal of neuropsychopharmacology.
[95] Yogesh K. Dwivedi,et al. Regional Distribution and Relative Abundance of Serotonin2c Receptors in Human Brain: Effect of Suicide , 2006, Neurochemical Research.
[96] C. Benkelfat,et al. Serotonin 1A Receptor Activation and Hypothermia in Humans: Lack of Evidence for a Presynaptic Mediation , 2002, Neuropsychopharmacology.
[97] Mary L. Schneider,et al. An in vivo comparison of cis- and trans-[18F]mefway in the nonhuman primate. , 2011, Nuclear medicine and biology.
[98] A. Meneses,et al. The effects of the 5-HT6 receptor agonist EMD and the 5-HT7 receptor agonist AS19 on memory formation , 2008, Behavioural Brain Research.
[99] N. Volkow,et al. Strategy for the Formation of Parametric Images under Conditions of Low Injected Radioactivity Applied to PET Studies with the Irreversible Monoamine Oxidase a Tracers [11C]Clorgyline and Deuterium-Substituted [11C]Clorgyline , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[100] Jeffrey H Meyer,et al. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. , 2007, Journal of psychiatry & neuroscience : JPN.
[101] Jian Liu,et al. The pyramidal neurons in the medial prefrontal cortex show decreased response to 5-hydroxytryptamine-3 receptor stimulation in a rodent model of Parkinson's disease , 2011, Brain Research.
[102] T. Blackburn,et al. Evidence for expression of the 5-hydroxytryptamine-2B receptor protein in the rat central nervous system , 1997, Neuroscience.
[103] A. Sleight,et al. Correlation between 5-HT7 receptor affinity and protection against sound-induced seizures in DBA/2J mice , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[104] M. Ferrari,et al. Selective seratonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial , 2001, The Lancet.
[105] Jun Li,et al. [Association of 5-HT(2A) receptor polymorphism and attention deficit hyperactivity disorder in children]. , 2002, Zhonghua yi xue za zhi.
[106] M. Bergström,et al. 11C-harmine as a tracer for monoamine oxidase A (MAO-A): in vitro and in vivo studies. , 1997, Nuclear medicine and biology.
[107] F. Vollenweider,et al. Psychological and Physiological Effects of MDMA (“Ecstasy”) after Pretreatment with the 5-HT2 Antagonist Ketanserin in Healthy Humans , 2000, Neuropsychopharmacology.
[108] F. Mauguière,et al. PET imaging of brain 5-HT1A receptors in the preoperative evaluation of temporal lobe epilepsy. , 2008, Brain : a journal of neurology.
[109] J. Neumaier,et al. Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder , 2011, Psychopharmacology.
[110] Alan A. Wilson,et al. Distribution of Vesicular Monoamine Transporter 2 Protein in Human Brain: Implications for Brain Imaging Studies , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[111] M. Seidel,et al. Differential pharmacotherapy for subgroups of fibromyalgia patients with specific consideration of 5-HT3 receptor antagonists , 2011, Expert opinion on pharmacotherapy.
[112] M. Buhot,et al. Hyperfunction of Muscarinic Receptor Maintains Long-Term Memory in 5-HT4 Receptor Knock-Out Mice , 2010, PloS one.
[113] R. Davidson,et al. In vivo kinetics of [F‐18]MEFWAY: A comparison with [C‐11]WAY100635 and [F‐18]MPPF in the nonhuman primate , 2011, Synapse.
[114] C. Halldin,et al. Quantitative Analysis of [11C]AZ10419369 Binding to 5-HT1B Receptors in Human Brain , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[115] F. Dauphin,et al. Serotonin 5-HT6 receptor blockade reverses the age-related deficits of recognition memory and working memory in mice , 2011, Behavioural Brain Research.
[116] Morten L. Kringelbach,et al. The personality trait openness is related to cerebral 5-HTT levels , 2009, NeuroImage.
[117] S. Cichon,et al. Investigation of the human serotonin 6 [5-HT6] receptor gene in bipolar affective disorder and schizophrenia. , 2000, American journal of medical genetics.
[118] Claus Svarer,et al. Brain imaging of serotonin 4 receptors in humans with [11C]SB207145-PET , 2010, NeuroImage.
[119] H. Diener,et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – A randomised proof-of-concept trial , 2010, Cephalalgia : an international journal of headache.
[120] Siegfried Kasper,et al. Multimodal imaging of human early visual cortex by combining functional and molecular measurements with fMRI and PET , 2008, NeuroImage.
[121] J. Mann,et al. Substance Abuse Disorder and Major Depression are Associated with the Human 5-HT1B Receptor Gene (HTR1B) G861C Polymorphism , 2003, Neuropsychopharmacology.
[122] Y. Ohno. Therapeutic Role of 5‐HT1A Receptors in The Treatment of Schizophrenia and Parkinson's Disease , 2011, CNS neuroscience & therapeutics.
[123] Pedro Rosa-Neto,et al. Stability of α-[11C]methyl-l-tryptophan brain trapping in healthy male volunteers , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[124] Anders Ettrup,et al. Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[125] G. Godeheu,et al. Paradoxical constitutive behavioral sensitization to amphetamine in mice lacking 5-HT2A receptors , 2007, Psychopharmacology.
[126] Rupert Lanzenberger,et al. Cortisol plasma levels in social anxiety disorder patients correlate with serotonin-1A receptor binding in limbic brain regions. , 2010, The international journal of neuropsychopharmacology.
[127] J. Ehlen,et al. In Vivo Resetting of the Hamster Circadian Clock by 5-HT7 Receptors in the Suprachiasmatic Nucleus , 2001, The Journal of Neuroscience.
[128] Victor W Pike,et al. 5‐HT radioligands for human brain imaging with PET and SPECT , 2013, Medicinal research reviews.
[129] H. Hasegawa,et al. Tryptophan hydroxylase and serotonin synthesis regulation , 2020, Handbook of Behavioral Neuroscience.
[130] A. Wesołowska,et al. The 5-HT6 receptor agonist EMD 386088 produces antidepressant and anxiolytic effects in rats after intrahippocampal administration , 2011, Psychopharmacology.
[131] David C. Reutens,et al. Increased serotonin receptor availability in human sleep: Evidence from an [18F]MPPF PET study in narcolepsy , 2006, NeuroImage.
[132] Alan A. Wilson,et al. Influence of a low dose of amphetamine on vesicular monoamine transporter binding: A PET (+)[11C]DTBZ study in humans , 2010, Synapse.
[133] Abraham Weizman,et al. Decreased platelet vesicular monoamine transporter density in habitual smokers , 2005, European Neuropsychopharmacology.
[134] D. Murphy,et al. Primary structure of the serotonin transporter in unipolar depression and bipolar disorder , 1995, Biological Psychiatry.
[135] Ceri H. Davies,et al. SB-699551-A (3-cyclopentyl-N-[2-(dimethylamino)ethyl]-N-[(4′-{[(2-phenylethyl)amino]methyl}-4-biphenylyl)methyl]propanamide dihydrochloride), a novel 5-ht5A receptor-selective antagonist, enhances 5-HT neuronal function: Evidence for an autoreceptor role for the 5-ht5A receptor in guinea pig brain , 2006, Neuropharmacology.
[136] D. S. Cowen,et al. 5-HT7 receptors activate the mitogen activated protein kinase extracellular signal related kinase in cultured rat hippocampal neurons , 2001, Neuroscience.
[137] W. Baaré,et al. Cognitive function is related to fronto-striatal serotonin transporter levels – a brain PET study in young healthy subjects , 2011, Psychopharmacology.
[138] V. Pike,et al. Synthesis, structure-affinity relationships, and radiolabeling of selective high-affinity 5-HT4 receptor ligands as prospective imaging probes for positron emission tomography. , 2010, Journal of medicinal chemistry.
[139] G. Kranz,et al. Reward and the serotonergic system , 2010, Neuroscience.
[140] Á. N. Chonchubhair. Selective serotonin reuptake inhibitors. , 1998, Anaesthesia.
[141] R. Silvestri,et al. Radiosynthesis and in vivo evaluation of [11C]-labelled pyrrole-2-carboxamide derivates as novel radioligands for PET imaging of monoamine oxidase A. , 2010, Nuclear medicine and biology.
[142] S. Leal,et al. Novel and previously reported single-nucleotide polymorphisms in the human 5-HT(1B) receptor gene: no association with cocaine or alcohol abuse or dependence. , 2001, American journal of medical genetics.
[143] P F Liddle,et al. Effects of rapid tryptophan depletion on brain 5-HT2 receptors: a PET study , 2001, British Journal of Psychiatry.
[144] G. Miller,et al. Nonmotor Symptoms of Parkinson's Disease Revealed in an Animal Model with Reduced Monoamine Storage Capacity , 2009, The Journal of Neuroscience.
[145] Giovanna Rizzo,et al. 5-HT2A receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study , 2003, Psychopharmacology.
[146] Claus Svarer,et al. Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome. , 2007, The international journal of neuropsychopharmacology.
[147] Richard E Carson,et al. Kinetic Modeling of the Serotonin 5-HT1B Receptor Radioligand [11C]P943 in Humans , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[148] Peter Herscovitch,et al. Reduced Serotonin Type 1A Receptor Binding in Panic Disorder , 2004, The Journal of Neuroscience.
[149] S. Tsai,et al. Association analysis of the 5-HT6 receptor polymorphism C267T in Alzheimer's disease , 1999, Neuroscience Letters.
[150] J. Sutcliffe,et al. The 5-HT7 receptor influences stereotypic behavior in a model of obsessive-compulsive disorder , 2007, Neuroscience Letters.
[151] D. Pandey,et al. Design, synthesis and structure-activity relationship of novel quinoxalin-2-carboxamides as 5-HT3 receptor antagonists for the management of depression. , 2010, Bioorganic & medicinal chemistry letters.
[152] Zsolt Szabo,et al. Quantitative PET Studies of the Serotonin Transporter in MDMA Users and Controls Using [11C]McN5652 and [11C]DASB , 2005, Neuropsychopharmacology.
[153] J. Palacios,et al. Serotonin receptors in the human brain—III. Autoradiographic mapping of serotonin-1 receptors , 1987, Neuroscience.
[154] Ramin V. Parsey,et al. Elevated Serotonin 1A Binding in Remitted Major Depressive Disorder: Evidence for a Trait Biological Abnormality , 2009, Neuropsychopharmacology.
[155] D. E. Nichols,et al. Serotonin receptors. , 2008, Chemical reviews.
[156] X. Codony,et al. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. , 2008, Pharmacology & therapeutics.
[157] T. Kozasa,et al. Regulation and Physiological Functions of G12/13-Mediated Signaling Pathways , 2009, Neurosignals.
[158] R Todd Ogden,et al. Modeling Considerations for 11C-CUMI-101, an Agonist Radiotracer for Imaging Serotonin 1A Receptor In Vivo with PET , 2008, Journal of Nuclear Medicine.
[159] Christine DeLorenzo,et al. In Vivo Quantification of Human Serotonin 1A Receptor Using 11C-CUMI-101, an Agonist PET Radiotracer , 2010, The Journal of Nuclear Medicine.
[160] C. Bai,et al. Cytokines and serotonin transporter in patients with major depression , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[161] D. Popa,et al. Contribution of 5-HT2 Receptor Subtypes to Sleep–Wakefulness and Respiratory Control, and Functional Adaptations in Knock-Out Mice Lacking 5-HT2A Receptors , 2005, The Journal of Neuroscience.
[162] Vibe G. Frokjaer,et al. Serotonin transporter binding in the hypothalamus correlates negatively with tonic heat pain ratings in healthy subjects: A [11C]DASB PET study , 2011, NeuroImage.
[163] V. Erspamer,et al. Identification of Enteramine, the Specific Hormone of the Enterochromaffin Cell System, as 5-Hydroxytryptamine , 1952, Nature.
[164] N. Volkow,et al. Translational Neuroimaging: Positron Emission Tomography Studies of Monoamine Oxidase , 2005, Molecular Imaging and Biology.
[165] C. Rowe,et al. In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with 18F-AV-133 , 2010, Journal of Nuclear Medicine.
[166] Robert B. Innis,et al. Effects of Early Life Stress on [11C]DASB Positron Emission Tomography Imaging of Serotonin Transporters in Adolescent Peer- and Mother-Reared Rhesus Monkeys , 2006, The Journal of Neuroscience.
[167] J. Holenz,et al. Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents. , 2006, Drug discovery today.
[168] R. Parsey,et al. Higher Serotonin 1A Binding in a Second Major Depression Cohort: Modeling and Reference Region Considerations , 2010, Biological Psychiatry.
[169] M. Yeager,et al. Candidate genes for anorexia nervosa in the 1p33–36 linkage region: serotonin 1D and delta opioid receptor loci exhibit significant association to anorexia nervosa* , 2003, Molecular Psychiatry.
[170] T. Branchek,et al. Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. , 1997, Life sciences.
[171] P. Bonaventure,et al. 5-HT7 receptor deletion enhances REM sleep suppression induced by selective serotonin reuptake inhibitors, but not by direct stimulation of 5-HT1A receptor , 2009, Neuropharmacology.
[172] Otto Muzik,et al. Human brain serotonin synthesis capacity measured in vivo with α‐[C‐11]methyl‐L‐tryptophan , 1998 .
[173] M Diksic,et al. Statistical mapping analysis of serotonin synthesis images generated in healthy volunteers using positron-emission tomography and alpha-[11C]methyl-L-tryptophan. , 2000, Journal of psychiatry & neuroscience : JPN.
[174] Sylvain Houle,et al. Positron Emission Tomography Quantification of [11C]-Harmine Binding to Monoamine Oxidase-A in the Human Brain , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[175] Yogesh Kumar Dwivedi,et al. Neuroprotective effect of a chuk-me-sun-dan on neurons from ischemic damage and neuronal cell toxicity. , 2006 .
[176] D. Kupfer,et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. , 2007, Nuclear medicine and biology.
[177] M. Grégoire,et al. Cerebral Monoamine Oxidase A Inhibition in Tobacco Smokers Confirmed With PET and [11C]Befloxatone , 2009, Journal of clinical psychopharmacology.
[178] S. Obayashi,et al. Synthesis and preliminary PET study of the 5‐HT7 receptor antagonist [11C]DR4446 , 2002 .
[179] E. Lacivita,et al. Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders. , 2011, Pharmacology & therapeutics.
[180] Pedro Rosa-Neto,et al. Measurement of brain regional alpha-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. , 2004, Archives of general psychiatry.
[181] H. Kung,et al. An improved radiosynthesis of [18F]AV-133: a PET imaging agent for vesicular monoamine transporter 2. , 2010, Nuclear Medicine and Biology.
[182] B. Bondy,et al. Association of 5-HT1B receptor gene and antisocial behavior in alcoholism , 2004, Journal of Neural Transmission.
[183] N. Volkow,et al. Comparison of monoamine oxidase a in peripheral organs in nonsmokers and smokers. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[184] G. Kennett,et al. Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression. , 1987, European journal of pharmacology.
[185] A. Wesołowska. Potential role of the 5-HT_6 receptor in depression and anxiety: an overview of preclinical data , 2010, Pharmacological reports : PR.
[186] Flemming Andersen,et al. Evaluation of the Novel 5-HT4 Receptor PET Ligand [11C]SB207145 in the Göttingen Minipig , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[187] G. Simig,et al. Medicinal chemistry of 5-HT5A receptor ligands: a receptor subtype with unique therapeutical potential. , 2010, Current topics in medicinal chemistry.
[188] Berend Olivier,et al. 5-HT1B receptors and aggression: a review. , 2005, European journal of pharmacology.
[189] Rupert Lanzenberger,et al. The Serotonin-1A Receptor in Anxiety Disorders , 2009, Biological Psychiatry.
[190] R Hen,et al. Enhanced aggressive behavior in mice lacking 5-HT1B receptor. , 1994, Science.
[191] Yong-Ku Kim,et al. Association Study between 5-HT1A Receptor Gene C(-1019)G Polymorphism and Panic Disorder in a Korean Population , 2010, Psychiatry investigation.
[192] R. Rodriguiz,et al. Vmat2 Heterozygous Mutant Mice Display a Depressive-Like Phenotype , 2007, The Journal of Neuroscience.
[193] Richard E Carson,et al. High-resolution imaging of brain 5-HT 1B receptors in the rhesus monkey using [11C]P943. , 2010, Nuclear medicine and biology.
[194] Zarrin Ghasemi,et al. Synthesis of new N-heteroaryl derivatives of 4-pyrones from kojic acid based Baylis–Hillman acetates , 2013, Chemistry of Heterocyclic Compounds.
[195] M. Laruelle,et al. Evaluation of the novel 5-HT6 receptor radioligand, [11C]GSK-215083 in human , 2008, NeuroImage.
[196] R Tannock,et al. The serotonin 5-HT1B receptor gene and attention deficit hyperactivity disorder , 2003, Molecular Psychiatry.
[197] R. Yoshimura,et al. Pharmacogenetic study of serotonin 6 receptor gene with antidepressant response in major depressive disorder in the Japanese population , 2010, Human psychopharmacology.
[198] D. Le Bars,et al. Synthesis and biological evaluation of potential 5-HT(7) receptor PET radiotracers. , 2011, European journal of medicinal chemistry.
[199] David Goldman,et al. Functional Genetic Variants that Increase Synaptic Serotonin and 5-HT3 Receptor Sensitivity Predict Alcohol and Drug Dependence , 2010, Molecular Psychiatry.
[200] H. Meltzer. The Role of Serotonin in Antipsychotic Drug Action , 1999, Neuropsychopharmacology.
[201] M. Mandelkern,et al. Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5‐HT3 receptor antagonist: a pilot study , 2008, Alimentary pharmacology & therapeutics.
[202] E. Marchetti-Gauthier,et al. 5-HT4 receptors: long-term blockade of K+ channels and effects on olfactory memory. , 1998, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.
[203] M. Macavoy,et al. Regional distribution and behavioral correlates of 5-HT2A receptors in Alzheimer's disease with [18F]deuteroaltanserin and PET , 2009, Psychiatry Research: Neuroimaging.
[204] P. Kalivas,et al. Substance abuse disorders. , 2012, Handbook of clinical neurology.
[205] M. Kung,et al. Ketanserin and tetrabenazine abolish aggression in mice lacking monoamine oxidase A , 1999, Brain Research.
[206] Lei Dong,et al. Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome. , 2007, Chinese medical journal.
[207] Lisa Weissfeld,et al. Altered brain serotonin 5-HT1A receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [carbonyl11C]WAY-100635. , 2005, Archives of general psychiatry.
[208] H. Nagawa,et al. Antiangiogenic effect of a selective 5-HT4 receptor agonist. , 2010, The Journal of surgical research.
[209] J. Witkin,et al. Constitutive deletion of the serotonin-7 (5-HT7) receptor decreases electrical and chemical seizure thresholds , 2007, Epilepsy Research.
[210] A. Meneses,et al. 5-HT1A receptors and memory , 2007, Neuroscience & Biobehavioral Reviews.
[211] Paul Cumming,et al. Effect of monoamine oxidase inhibition on amphetamine‐evoked changes in dopamine receptor availability in the living pig: A dual tracer PET study with [11C]harmine and [11C]raclopride , 2006, Synapse.
[212] Julie C Price,et al. Reduced 5-HT2A receptor binding after recovery from anorexia nervosa , 2002, Biological Psychiatry.
[213] G. Fischbach,et al. Neurotransmitters decrease the calcium conductance activated by depolarization of embryonic chick sensory neurones. , 1981, The Journal of physiology.
[214] Jeih-San Liow,et al. PET [11C]DASB imaging of serotonin transporters in patients with alcoholism. , 2007, Alcoholism, clinical and experimental research.
[215] R. Narendran,et al. Positron emission tomography imaging of amphetamine‐induced dopamine release in the human cortex: A comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride , 2009, Synapse.